EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Antibody-Drug Conjugates in the Treatment of Esophageal Cancer

Dapeng Wu, Wei Chen, Qi Zhao, Wenjing Zhu, Jian Xu

Current Treatment Options in Oncology · 2026

DOI: 10.1007/s11864-026-01411-2 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Current Treatment Options in Oncology, 2026. Verfasst von Dapeng Wu und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology, Qingdao Municipal Hospital, Qingdao University, Qingdao, China. Hauptthemen laut MEDLINE: Immunoconjugates, Esophageal Neoplasms, Antineoplastic Agents, Immunological. Die Arbeit nennt 80 Literaturangaben. Gefördert von: Natural Science Foundation of Qingdao Municipality.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Esophageal cancer remains one of the most lethal malignancies worldwide, with particularly poor outcomes following disease progression after first-line chemoimmunotherapy. Antibody-drug conjugates (ADCs) have emerged as a transformative therapeutic class that combines the targeting precision of monoclonal antibodies with potent cytotoxic payloads, enabling selective tumor cell killing while minimizing off-target toxicity. In the management of advanced esophageal cancer, I advocate for the integration of ADCs as a therapeutic option following progression on first-line chemoimmunotherapy. For patients with human epidermal growth factor receptor 2 (HER2)-positive gastroesophageal junction adenocarcinoma, trastuzumab deruxtecan is my preferred choice based on its superior overall survival benefit and robust bystander killing effect, which also confers activity in HER2-low tumors. For HER2-negative gastroesophageal adenocarcinoma, trophoblast cell-surface antigen 2 represents a promising target given its high prevalence of moderate to strong expression in nearly 80% of cases, and sacituzumab tirumotecan is currently under phase III investigation in this setting. In esophageal squamous cell carcinoma, I recommend biomarker-guided selection among ADCs targeting B7-H3, given its overexpression in over 90% of cases. For Nectin-4-expressing tumors, enfortumab vedotin may be considered as a later-line alternative despite modest activity. Notably, the bispecific ADC targeting both epidermal growth factor receptor and human epidermal growth factor receptor 3, BL-B01D1, has demonstrated compelling efficacy in immunotherapy-refractory esophageal squamous cell carcinoma, and I consider it a breakthrough option in this subtype. For claudin-18.2-positive gastroesophageal junction adenocarcinoma, several ADCs including CMG901, IBI343, and tecotabart vedotin represent promising later-line choices. I emphasize that patient selection should be guided by validated predictive biomarkers, and treatment decisions must account for distinctive toxicity profiles, particularly interstitial lung disease with trastuzumab deruxtecan. Finally, I strongly support advancing ADCs into earlier lines of therapy and perioperative settings through well-designed clinical trials to further improve long-term outcomes in this aggressive malignancy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ImmunoconjugatesEsophageal NeoplasmsAntineoplastic Agents, ImmunologicalHumansMolecular Targeted TherapyErb-b2 Receptor Tyrosine KinasesTreatment OutcomeBiomarkers, Tumor

Stichwörter der Autor:innen

Antibody–drug conjugateB7-H3CLDN18.2Esophageal cancerHER2TROP2

Substanzen

ImmunoconjugatesErb-b2 Receptor Tyrosine KinasesBiomarkers, TumorAntineoplastic Agents, Immunological

Autor:innen und Institutionen

  • Department of Oncology, Qingdao Municipal Hospital, Qingdao University, Qingdao, China.
  • Department of Oncology, Qingdao Hospital, University of Health and Rehabilitation Sciences (Qingdao Municipal Hospital), Qingdao, China.
  • College of Pharmacy, Dalian Medical University, Dalian, China.
  • Medical Research Department, Qingdao Hospital, University of Health and Rehabilitation Sciences (Qingdao Municipal Hospital), Qingdao, China. zhuwj@uhrs.edu.cn.
  • Department of Oncology, Qingdao Municipal Hospital, Qingdao University, Qingdao, China. 290821357@qq.com.
  • Department of Oncology, Qingdao Hospital, University of Health and Rehabilitation Sciences (Qingdao Municipal Hospital), Qingdao, China. 290821357@qq.com.

Förderung

  • Natural Science Foundation of Qingdao Municipality

Zitieren

APA

Wu, D., Chen, W., Zhao, Q., Zhu, W., & Xu, J. (2026). Antibody-Drug Conjugates in the Treatment of Esophageal Cancer. Current Treatment Options in Oncology. https://doi.org/10.1007/s11864-026-01411-2

Vancouver

Wu D, Chen W, Zhao Q, Zhu W, Xu J. Antibody-Drug Conjugates in the Treatment of Esophageal Cancer. Current Treatment Options in Oncology. 2026. doi:10.1007/s11864-026-01411-2

BibTeX
@article{Wu2026,
  author = {Wu, Dapeng and Chen, Wei and Zhao, Qi and Zhu, Wenjing and Xu, Jian},
  title = {Antibody-Drug Conjugates in the Treatment of Esophageal Cancer},
  journal = {Current Treatment Options in Oncology},
  year = {2026},
  doi = {10.1007/s11864-026-01411-2}
}
Kostenlos starten →